Finally, a large-scale clinical study has revealed that mutations in the SP1 binding site of the promoter in ABCG1 reduced SP1 binding and increased risk of myocardial infarction and ischemic heart disease [39]. This evidence concerns the gene ABCG1 and myocardial infarction.